Animal Or Plant Cell Patents (Class 424/93.7)
  • Patent number: 10722577
    Abstract: It has been discovered that administering therapeutically effective amounts of an antibiotic that kills Gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTL)-induced killing and/or by damage to endothelial microvasculature, including Radiation GI syndrome, GvHD disease, inflammatory diseases and autoimmune diseases.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: July 28, 2020
    Assignee: Sloan Kettering Institute for Cancer Research
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick
  • Patent number: 10716809
    Abstract: Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of peripheral blood mononuclear cells (PBMCs) from a sample of peripheral blood; (b) specifically selecting CD8+ T cells that also express PD-1 and/or TIM-3 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: July 21, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Alena Gros, Steven A. Rosenberg
  • Patent number: 10711244
    Abstract: The present invention relates to a method for producing mammalian neural plate border stem cells (NPBSCs), comprising: (a) differentiation of mammalian pluripotent stem cells by (a-i) culturing mammalian pluripotent stem cells in pluripotent stem cell medium for about 24 to about 96 hours, wherein the pluripotent stem cell medium comprises: (i) an inhibitor of the activin/TGF-? signalling pathway; (ii) an inhibitor of the BMP signalling pathway; (iii) an activator of the canonical WNT signalling pathway; and (iv) an activator of the Hedgehog signalling pathway; subsequently (a-ii) culturing the cells obtained in step (a-i) for about 24 to about 96 hours in a neural medium, wherein the neural medium comprises: (i) an inhibitor of the Activin/TGF-? signalling pathway; (ii) an inhibitor of the BMP signalling pathway; (iii) an activator of the canonical WNT signalling pathway; and (iv) an activator of the Hedgehog signalling pathway; subsequently (a-iii) culturing the cells obtained in step (a-ii) for about 24 to
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: July 14, 2020
    Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Hans R. Schoeler, Jared L. Sterneckert, Michael Glatza, Peter Reinhardt
  • Patent number: 10709781
    Abstract: Methods for priming of vaccines including administering to a patient a composition including one or more integrin activating compounds capable of adjuvanting an antigen and capable of adjuvanting one or more antigens contained in a vaccine preparation.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: July 14, 2020
    Assignee: 7 Hills Pharma LLC
    Inventors: Darren G. Woodside, Peter Vanderslice, Upendra K. Marathi
  • Patent number: 10709765
    Abstract: The present invention provides a composition for inhibiting the survival or growth of a tubercle bacillus, containing a material which induces the polarization of a macrophage into an M1 macrophage, and a method for inhibiting the survival or growth of the tubercle bacillus by using the composition.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: July 14, 2020
    Assignee: THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
    Inventor: Chang-Hwa Song
  • Patent number: 10704026
    Abstract: Methods are provided for long term culture of mammalian intestinal cells. Cultures are initiated with fragments of mammalian intestinal tissue, which are then maintained embedded in a gel substrate that provides an air-liquid interface. Intestinal epithelium in cultures of the invention can be continuously grown for extended periods of time. Mammalian intestinal cells cultured by the methods of the invention recapitulate features of intestinal growth in vivo.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: July 7, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Calvin Jay Kuo, Akifumi Ootani
  • Patent number: 10702556
    Abstract: The present invention relates to compositions and methods of inducing angiogenesis and methods of treating a pathology that would benefit from angiogenesis by use of a composition comprising partially purified intact mitochondria and/or ruptured mitochondria derived therefrom.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: July 7, 2020
    Assignee: Minovia Therpautices Ltd.
    Inventors: Natalie Yivgi-Ohana, Uriel Halavee, Shmuel Bukshpan
  • Patent number: 10696945
    Abstract: A composition including adult pluripotent olfactory stem cells is provided. The adult pluripotent olfactory stem cells are obtained by culturing a cell mixture from an olfactory tissue of a mammal in media containing growth factors and then isolating cells which express B-lymphoma moloney murine leukemia virus insertion region-1 (Bmi-1).
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: June 30, 2020
    Assignee: China Medical University
    Inventors: Woei-Cherng Shyu, Chung-Y. Hsu, Der-Yang Cho, Chen-Huan Lin, Wei Lee, San-Yuan Chen, Long-Bin Jeng, Chang-Hai Tsai
  • Patent number: 10688152
    Abstract: One aspect of the present invention provides methods of treating a viral infection in a subject including administrating a therapeutically effective amount of at least one Wnt ligand protein selected from Wnt1, Wnt2, Wnt2B, Wnt3, Wnt3A, Wnt4, Wnt5A, Wnt5B, Wnt6, Wnt7A, Wnt7B, Wnt8A, Wnt8B, Wnt9A, Wnt9B, Wnt10A, Wnt10B, Wnt11 and Wnt16. In one embodiment, the subject is a human and the infection is a human immunodeficiency virus infection. Another aspect provides drug combinations for treating viral infections.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: June 23, 2020
    Assignee: Rush University Medical Center
    Inventor: Lena Al-Harthi
  • Patent number: 10677799
    Abstract: Ctsk is used as a marker to identify, track, and manipulate Ctsk positive cartilaginous stem cells for cartilage repair and regeneration in vitro and in vivo.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 9, 2020
    Assignee: Rhode Island Hospital
    Inventors: Wentian Yang, Nikhil Thakur
  • Patent number: 10675307
    Abstract: Embodiments of the present invention provide a population of purified perivascular stem cells (PSC) or induced pluripotent stem cells (iPS) and a supernatant of stem cell free from the stem cell, a composition comprising any of these, and a method of using and making them.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: June 9, 2020
    Assignee: The Regents of the University of California
    Inventors: B. Chia Soo, Kang Ting, Bruno M. Peault
  • Patent number: 10675382
    Abstract: The present invention addresses the problem of providing a method for obtaining Schwann cells directly (by direct reprogramming) without passing through pluripotent stem cells, such as ES cells or iPS cells. As a means for solving this problem, the present invention provides a method for preparing Schwann cells that includes a step of introducing into somatic cells of a mammal at least one gene selected from the group consisting of SOX10 genes and KROX20 genes, or an expression product thereof.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: June 9, 2020
    Assignee: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
    Inventors: Yoshihiro Sowa, Tsunao Kishida, Osam Mazda
  • Patent number: 10668484
    Abstract: A fluid handling system is provided that includes a controller, a plurality of valves, a pump, and an interface in communication with the controller. The valves can be operatively connected with a conduit to along a flow path. Each of the valves is controlled by the controller for selective movement between a first position and a second position. The first position closes the flow path, while the second position opens the flow path. The pump can be operatively connected with the conduit and the is controlled by the controller for selective pumping of fluid through the flow path. The interface allows selective definition of the flow path through the valves.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: June 2, 2020
    Assignee: Alfa Wassermann, Inc.
    Inventors: Kurt Spiegel, Blaine J Marsh, Christopher A DeBlasis, Fernando J Garcia, Ian Eric Lynes, Raymond A Hathaway
  • Patent number: 10668111
    Abstract: The present invention relates to treatment of pulmonary fibrosis with umbilical mesenchymal stem cell.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: June 2, 2020
    Assignees: NATIONAL YANG MING UNIVERSITY
    Inventor: Yu-Show Fu
  • Patent number: 10668105
    Abstract: The present invention provides novel stem cell compositions having significant therapeutic and practical advantages, as well as methods of preparing and using such compositions for the treatment and prevention of injury and disease in patients. The invention may be applied to stem cell populations isolated from a wide variety of animals, including humans, and tissues. In particular applications, the invention is used to prepare a stem cell composition from a collagen-based tissue, such as adipose tissue, isolated from a patient, and the stem cell composition is subsequently provided to a site of actual or potential injury in the patient. The invention further includes related kits comprising the stem cell compositions, which are remarkably stable and retain viability and efficacy during storage and shipment.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: June 2, 2020
    Assignee: VetStem Biopharma, Inc.
    Inventors: Robert J. Harman, Jr., Theodore T. Sand
  • Patent number: 10669528
    Abstract: The methods and compositions described herein relate to producing, expanding, enriching, and/or maintaining hematopoietic stem cells ex vivo by treating the cells with an agent(s) that exhibits two or more activities selected from modulation of histone methylation; inhibition of TGF? signaling; inhibition of p38 signaling; activation of canonical Wnt signaling; and modulation of histone acetylation. In some embodiments, the technology described herein relates to transplantation of hematopoietic stem cells.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: June 2, 2020
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Derrick J. Rossi, Wataru Ebina, Morag Stewart, Paula Gutierrez-Martinez, Lee L. Rubin, Lance Davidow
  • Patent number: 10669525
    Abstract: Means which enables preparation of a thick cell aggregate by a simple process without an operation of detaching and stacking of cells is disclosed. The method for preparing a three-dimensional cell aggregate by the present invention comprises: a cell encasing step of placing a cell suspension in a cell container; and a pressure application step of applying pressure to cells in the container. The cell encasing step and the pressure application step may be carried out a plurality of times. By the present invention, a thick, robust cell aggregate can be obtained by a simple operation of applying pressure to a cell suspension or a medium containing cells. Since the method does not require an operation of stacking a plurality of cell sheets, the cells are hardly damaged, and the conditions of the cells can be favorably maintained, so that the cells can be advantageously used as a tissue piece for transplantation.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: June 2, 2020
    Assignees: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    Inventors: Utako Yokoyama, Yoshihiro Ishikawa, Makoto Kaneko, Shinya Sakuma, Fumihito Arai
  • Patent number: 10660987
    Abstract: Hydrodynamic methods for conformally coating non-uniform size cells and cell clusters for implantation, thus preventing immune rejection or inflammation or autoimmune destruction while preserving cell functionality. A method for conformally coating cells and c clusters with hydrogels that are biocompatible, mechanically and chemically stable and porous, with an appropriate pore cut-off size. The methods of the invention are advantageously reproducible and result in a relatively high yield of coated versus non-coated cell clusters, without compromising cell functionality. Conformal coating devices configured to perform the methods of the invention, methods of optimally utilizing said devices and purifying the coated islets, and coated biomaterials made by said methods.
    Type: Grant
    Filed: April 28, 2012
    Date of Patent: May 26, 2020
    Assignee: CONVERGE BIOTECH INC.
    Inventors: Jeffrey Hubbell, Alice Tomei
  • Patent number: 10653816
    Abstract: Hydrodynamic methods for conformally coating non-uniform size cells and cell clusters for implantation, thus preventing immune rejection or inflammation or autoimmune destruction while preserving cell functionality. A method for conformally coating cells and cell clusters with hydrogels that are biocompatible, mechanically and chemically stable and porous, with an appropriate pore cut-off size. The methods of the invention are advantageously reproducible and result in a relatively high yield of coated versus non-coated cell clusters, without compromising cell functionality. Conformal coating devices configured to perform the methods of the invention, methods of optimally utilizing said devices and purifying the coated islets, and coated biomaterials made by said methods.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: May 19, 2020
    Assignee: CONVERGE BIOTECH INC.
    Inventors: Jeffrey Hubbell, Alice Tomei
  • Patent number: 10655121
    Abstract: A system for accelerating and/or inhibiting the migration of cells by applying a time-varying magnetic field to induce eddy currents that promote electrotaxis (galvanotaxis) of cells without the need for chemokines or glucose. The present invention can also be used to study and quantify the metastatic potential of different cell lines.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: May 19, 2020
    Assignee: Ohio State Innovation Foundation
    Inventors: Vish Subramaniam, Joseph West, Emily Alkandry, Mohd Nasser, Dinesh Ahirwar, Ramesh Ganju
  • Patent number: 10655103
    Abstract: An isolated mammalian progenitor cell or its progeny, isolated from articular cartilage, is disclosed. Further is disclosed an equine progenitor cell isolated from the surface zone of equine articular cartilage tissue and uses thereof. Also disclosed are a method of tissue repair, a medicament, and a method of treating mammalian cartilage damage using such progenitor cells or progeny.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: May 19, 2020
    Assignee: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
    Inventors: Charles William Archer, Helen Elizabeth McCarthy
  • Patent number: 10656065
    Abstract: Systems and methods for uniquely identifying fluid-phase products by endowing them with fingerprints composed of dispersed colloidal particles, and by reading out those fingerprints on demand using Total Holographic Characterization. A library of chemically inert colloidal particles is developed that can be dispersed into soft materials, the stoichiometry of the mixture encoding user-specified information, including information about the host material. Encoded information then can be recovered by high-speed analysis of holographic microscopy images of the dispersed particles. Specifically, holograms of individual colloidal spheres are analyzed with predictions of the theory of light scattering to measure each sphere's radius and refractive index, thereby building up the distribution of particle properties one particle at a time. A complete analysis of a colloidal fingerprint requires several thousand single-particle holograms and can be completed in ten minutes.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: May 19, 2020
    Assignee: NEW YORK UNIVERSITY
    Inventors: David G. Grier, David B. Ruffner, Aaron Yevick, Mark Hannel
  • Patent number: 10640749
    Abstract: Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: May 5, 2020
    Assignees: NC MEDICAL RESEARCH INC., ASKA PHARMACEUTICAL CO., LTD., MITSUI SUMITOMO INSURANCE CARE NETWORK CO., LTD.
    Inventors: Osamu Honmou, Kazuo Hashi, Teiji Uede
  • Patent number: 10639264
    Abstract: A mesenchymal stem cell extract and its use are provided, wherein the mesenchymal stem cell extract comprises a trophic factor(s), such as bone morphogenetic protein-7 (BMP-7), stromal cell-derived factor-1 (SDF-1), vascular endothelial growth factor (VEGF), C-X-C chemokine receptor type-4 (CXCR4), brain-derived neurotrophic factor (BDNF), and/or interleukin-17 (IL-17), and wherein the extract is especially suitable for repairing skin aging.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: May 5, 2020
    Assignee: GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD.
    Inventors: Shinn-Zong Lin, Horng-Jyh Harn, Tzyy-Wen Chiou, Po-Cheng Lin
  • Patent number: 10639400
    Abstract: A method for coupling a body conduit to tissue includes engaging an implant about an outer surface of a catheter. The implant receives a bioactive agent having tissue growth properties. The method involves inserting the catheter through the body conduit and into a tissue opening across a resected area, positioning the implant in the resected area, inflating a balloon to anchor the catheter within the tissue opening such that the implant bridges the body conduit and the tissue opening across the resected area, and maintaining the catheter and the implant in vivo to enable the bioactive agent to secure the implant in the resected area to permanently bridge the body conduit and the tissue opening.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: May 5, 2020
    Assignee: COVIDIEN LP
    Inventors: Joe D. Sartor, Anthony B. Ross, Stephen Wohlert
  • Patent number: 10633632
    Abstract: This invention provides disc stem cells, processes for obtaining and culturing disc stem cells, and methods for repairing damaged or diseased disc tissue comprising the use of the disc stem cells of the invention.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: April 28, 2020
    Assignee: DiscGenics, Inc.
    Inventors: Valery Kukekov, Umar Akbar, Christopher Duntsch
  • Patent number: 10632229
    Abstract: The present invention relates generally to methods and materials for use in the production of implants, particularly luminal tissue implants, where the implants are engineered by seeding of an acellular scaffold or matrix with muscle cell precursors and fibroblasts, for example injection seeding using particular ratios of cells. The present invention provides methods for producing tissue engineered constructs for implantation into a subject which can utilise novel seeding processes described herein for improved cell engraftment and differentiation. In addition, the invention describes methods for treating an individual by implantation of the engineered constructs or tissues of the invention.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: April 28, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Paolo Decoppi, Luca Urbani, Anna Urciuolo
  • Patent number: 10624932
    Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: April 21, 2020
    Assignee: REBIOTIX, INC.
    Inventors: Lee A. Jones, Courtney R. Jones, Edwin J. Hlavka, Ryan D. Gordon
  • Patent number: 10624838
    Abstract: The present invention relates to the use of gingival fibroblast-derived products to reduce hair loss and promote hair growth. Specifically, the invention relates to a product derived from gingival fibroblasts to be used in the treatment or prevention of alopecia, as well as in the promotion of natural hair growth and/or in the control of natural hair loss.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: April 21, 2020
    Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT DE RADIOPROTECTION ET DE SURETE NUCLEAIRE, ETAT FRANCAIS—MINISTERE DE AL DEFENSE—DIRECTION CENTRALE DU SERVICE DE SANTE DES ARMEES, UNIVERSITE PARIS DESCARTES
    Inventors: Antoine Lafont, Bernard Coulomb, Jean-Jacques Lataillade, Christine Linard
  • Patent number: 10617792
    Abstract: The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: April 14, 2020
    Assignee: MicroVascular Tissues, Inc.
    Inventors: Dale R. Peterson, Ralph-Heiko Mattern, Corey Wilson, Kevin L. Ohashi
  • Patent number: 10617812
    Abstract: A system for obtaining plasma enriched in platelets is disclosed which is closed to the atmosphere. The system includes: a collection tube containing an anticoagulant portion and a separation gel; a first collection syringe adapted to collect a portion of fluid relatively depleted in platelets from said collection tube after centrifugation; and a second collection syringe adapted to collect plasma enriched in platelets from said collection tube after centrifugation, said second collection syringe further comprising a filter unit adapted to filter cells included in said plasma enriched in platelets.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: April 14, 2020
    Assignee: ESTAR TECHNOLOGIES LTD
    Inventor: Aaron Esteron
  • Patent number: 10613515
    Abstract: The example systems, methods, and/or computer-readable media described herein help with design of highly accurate models of un-erupted or partially erupted teeth and help fabricate of aligners for un-erupted or partially erupted teeth. Automated agents that use machine learning models to parametrically represent three-dimensional (3d) virtual representations of teeth as 3D descriptors in a 3D descriptor space are provided herein. In some implementations, the automated agents described herein provide instructions to fabricate aligners for at least partially un-erupted teeth using representative 3D descriptor(s) of a tooth type.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: April 7, 2020
    Assignee: Align Technology, Inc.
    Inventors: Christopher Eric Cramer, Jeeyoung Choi
  • Patent number: 10604756
    Abstract: The present invention relates to methods for protecting against damage caused by radiation and/or chemotherapy, and methods for treating bone marrow damage by reducing/inhibiting Latexin expression and/or Latexin activity. The methods comprise administering to a subject in need thereof a pharmaceutical composition comprising an antagonist that reduces expression and/or activity of latexin, wherein latexin is a latexin polynucleotide variant and/or a latexin polypeptide variant that binds to the antagonist.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: March 31, 2020
    Assignee: University of Kentucky Research Foundation
    Inventors: Gary Van Zant, Ying Liang, Yi Liu
  • Patent number: 10597637
    Abstract: The present invention provides Jagged 1 and Frizzled 4 as cell surface markers for isolating human cardiomyogenic ventricular progenitor cells, in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Thus, the invention provides human ventricular progenitor (HVP) cells. The invention provides in vitro methods of the separation of Islet 1+ Jagged 1+ ventricular progenitor cells and/or Islet 1+/Frizzled 4+ ventricular progenitor cells and/or Islet 1+/Jagged 1+/Frizzled 4+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated Jagged 1+ and/or Frizzled 4+ventricular progenitor cells are also provided. Methods of in vivo use of Jagged 1+ and/or Frizzled 4+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the Jagged 1+ and/or Frizzled 4+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: March 24, 2020
    Assignee: Procella Therapeutics AB
    Inventors: Kenneth R. Chien, Xiaojun Lian
  • Patent number: 10597638
    Abstract: Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods of using such cell lines to screen for compounds that play a role in regulating a variety of processes.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: March 24, 2020
    Assignee: BIORESTORATIVE THERAPIES, INC.
    Inventors: Francisco Javier Silva, Mark Weinreb, Amit N. Patel, David A. Bull
  • Patent number: 10597398
    Abstract: To obtain a novel therapeutic drug for a malignant tumor or fibrosis. Used is a compound represented by formula (1), a salt thereof, or a solvate thereof. Also used is a therapeutic drug for a malignant tumor or a therapeutic drug for fibrosis, comprising a compound represented by formula (1), a salt thereof, or a solvate thereof.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: March 24, 2020
    Assignees: National University Corporation Tottori University, KanonCure, Inc.
    Inventors: Goshi Shiota, Noriko Itaba, Minoru Morimoto, Hiroyuki Oka, Kenichiro Abe, Hiroki Shimizu, Yohei Kouno, Satoshi Yokogi
  • Patent number: 10590381
    Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: March 17, 2020
    Assignee: Celularity, Inc.
    Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
  • Patent number: 10590180
    Abstract: The present invention discloses immune function development promoters and growth promoters comprising CCL25. The development of immune functions in a subject can be promoted by ingesting an immune function development promoter according to the present invention. Moreover, growth of a subject can be promoted by ingesting a growth promoter according to the present invention.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: March 17, 2020
    Assignee: NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITY
    Inventor: Kazutoshi Sayama
  • Patent number: 10590387
    Abstract: Provided herein are isolated CD133+ cells, such as human CD133+ cells, that have been expanded in culture and populations of isolated CD133+ cells that have been expanded in culture. The cells express transcription factors, growth factors, or a combination thereof, at altered levels compared to a naturally occurring CD133+ cell. Also provided are methods, including methods for expanding CD133+ cells and methods for using CD133+ cells.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: March 17, 2020
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Larry Denner, Randall J. Urban, Yvonne Bodenburg
  • Patent number: 10584316
    Abstract: Described here are three-dimensional microenvironment niches prepared from biomaterial compositions that support growth and self renewal of stem cells. The invention also provides methods for inducing pluripotency in a somatic cell using chemical compounds, as well as methods for screening for compounds that can induce pluripotency in a somatic cell.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: March 10, 2020
    Inventor: Babak Esmaeli-Azad
  • Patent number: 10570370
    Abstract: Provided are a method of preparing retinal ganglion cells by differentiation of stem into retinal ganglion cells, retinal ganglion cells differentiated by the method, a method of screening for a death inhibitor or a proliferation promoter of retinal ganglion cells using the retinal ganglion cells differentiated by the method, a kit of screening for the death inhibitor or the proliferation promoter of retinal ganglion cells including the retinal ganglion cells differentiated by the method, a pharmaceutical composition for treating glaucoma or optic neuropathy including the retinal ganglion cells, a method of treating glaucoma or optic neuropathy including the step of administering the retinal ganglion cells to a subject suspected of having glaucoma or optic neuropathy, and a method of preparing a mature retinal ganglion cell line.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: February 25, 2020
    Assignees: Seoul National University R&DB Foundation, Seoul National University Hospital
    Inventors: Sung Sup Park, Ji Yeon Kim
  • Patent number: 10568913
    Abstract: The present invention relates to methods for generating mature insulin-producing ?-like cells comprising the steps: (a) isolating, purifying and/or enriching ?-cell progenitor cells from a population of cells; (b) differentiation of the ?-cell progenitor cells into immature insulin-producing ?-like cells; and (c) maturation of the immature insulin-producing ?-like cells into mature insulin-producing ?-like cells, comprising exposing the immature insulin-producing ?-like cells to calcitriol or an analogue thereof. More particularly, the present invention relates to methods for generating mature insulin-producing ?-like cells for use in treating diabetes.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: February 25, 2020
    Assignee: Healthregen PTY LTD
    Inventor: Fang-Xu Jiang
  • Patent number: 10561741
    Abstract: Described herein are nanoparticle-based compositions, kits and methods and platforms for delivering one or more nucleic acids to a myeloid cell.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: February 18, 2020
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Paolo Serafini, Jennifer Vella, Vincenzo Bronte, Pirouz Daftarian, Angel Kaifer, Serena Zilio
  • Patent number: 10563175
    Abstract: The present disclosure relates generally to methods and compositions useful in cell and tissue biology and therapeutics. In particular, an in vitro method for differentiating pluripotent cells into endothelial colony forming cell-like cells (ECFC-like cells) is provided. A purified human cell population of NRP-1+CD31+ ECFC-like cells is provided, wherein at least some of the cells in the population have a high proliferation potential. Therapeutic and test agent screening methods for using the cell populations of the present disclosure are provided.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: February 18, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Mervin Yoder, Nutan Prasain
  • Patent number: 10561742
    Abstract: Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: February 18, 2020
    Assignee: The Penn State Research Foundation
    Inventors: Gong Chen, Ziyuan Guo, Zheng Wu
  • Patent number: 10561685
    Abstract: This disclosure relates to a cellular-based therapies for modulating the level of regulatory T cells (Treg) and/or the level of pro-inflammatory T cells (Th17/Th1). To provide these therapeutic effects, a combination comprising at least one a cellular pro-tolerogenic preparation and at least one a cellular pro-inflammatory preparation are administered sequentially.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: February 18, 2020
    Assignee: CANADIAN BLLOOD SERVICES
    Inventors: Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
  • Patent number: 10557116
    Abstract: Compositions and methods of using cells derived from umbilical cord tissue to stimulate and support lung tissue angiogenesis, to improve blood flow to lung tissue, to regenerate, repair, and improve lung tissue damaged by lung disease, disorder and/or injury, and to protect lung tissue from damage caused by lung disease, disorder and/or injury in a patient.
    Type: Grant
    Filed: December 19, 2009
    Date of Patent: February 11, 2020
    Assignee: DePuy Synthes Products, Inc.
    Inventors: David C. Colter, Anthony J. Kihm, Christine K. Ward, Anna Gosiewska
  • Patent number: 10557124
    Abstract: The invention disclosed herein generally relates to methods and systems for converting stem cells into specific tissue(s) or organ(s) through directed differentiation. In particular, the invention disclosed herein relates to methods and systems for promoting definitive endoderm formation from pluripotent stem cells. The invention disclosed herein further relates to methods and systems for promoting ventral-anterior foregut spheroid tissue formation, 3-dimensional lung tissue formation, and lung organoid tissue formation produced in vitro from the described methods.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: February 11, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jason Spence, Briana Dye
  • Patent number: 10550182
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: February 4, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Leonie Alten, Dominik Maurer, Steffen Walter, Sebastian Bunk
  • Patent number: 10550369
    Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: February 4, 2020
    Assignee: Mesoblast International Sarl
    Inventors: Samson Tom, Christopher Ton, Alla Danilkovitch